Is HSDB 8203 Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use HSDB 8203? Is HSDB 8203 safe for nursing mother and child? Does HSDB 8203 extracts into breast milk? Does HSDB 8203 has any long term or short term side effects on infants? Can HSDB 8203 influence milk supply or can HSDB 8203 decrease milk supply in lactating mothers?

It promotes pancreatic insulin secretion by inhibiting the DPP-4 enzyme that degrades the GLP-1 and GIP intestinal hormones involved in the physiological regulation of glucose, which are activated by eating (EMA 2016, Baetta 2011, Scheen 2011). Administered orally, once a day. Common side effects are upper respiratory tract infections, urinary tract infections, gastrointestinal disorders, rash and headaches (EMA, 2016). Low risk of hypoglycemia in monotherapy (EMA, 2015, Scheen 2011). Doses up to 16 times higher than normal for 2 weeks did not produce side effects (EMA, 2015). Since the last update we have not found published data on its excretion in breast milk. Its pharmacokinetic data (EMA 2015, Scheen 2011): low molecular weight, low percentage of binding to plasma proteins and very long half-life) make it likely it will pass into breast milk in concentrations that could be significant. Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity. Diet, exercise, and breastfeeding improve blood sugar levels. Among the antidiabetics of this same group, saxagliptin and vildagliptin would be preferable due to their short half-life (less than 3 hours). See below the information of these related products:

No information is available on the clinical use of HSDB 8203 during breastfeeding. If HSDB 8203 is required by the mother, it is not a reason to discontinue breastfeeding. However, an alternate drug may be preferred, especially while nursing a newborn or preterm infant. Saxagliptin has a shorter half-life than the other dipeptidyl-peptidase IV inhibitors and linagliptin is highly protein bound, so these might be better choices among drugs in this class for nursing mothers. Monitoring of the breastfed infant's blood glucose is advisable during maternal therapy with HSDB 8203.[1]